EP3706763A1 - Gemcitabine for Muscle Invasive Bladder Cancer Therapy
Summary
The European Patent Office published patent application EP3706763A1 on April 15, 2026, filed by TARIS Biomedical LLC with inventors Christopher Cutie and Dennis Giesing. The application covers gemcitabine (IPC A61K 31/7068) for use in induction and maintenance therapy for muscle invasive bladder cancer. The patent designates all European contracting states including Germany, France, the United Kingdom, Italy, and Spain.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 72 changes logged to date.
What changed
EPO Patent Bulletin entry for EP3706763A1 records the publication of TARIS Biomedical LLC's European patent application for gemcitabine pharmaceutical compositions for treating muscle invasive bladder cancer. The application covers both induction and maintenance therapy uses of the antineoplastic agent.
Pharmaceutical companies developing or commercializing gemcitabine-based bladder cancer treatments should review this filing for potential freedom-to-operate implications. Competitors in the urological oncology space should monitor the prosecution of this application through to grant or rejection.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GEMCITABINE FOR USE IN INDUCTION AND MAINTENANCE THERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Publication EP3706763A1 Kind: A1 Apr 15, 2026
Applicants
TARIS Biomedical LLC
Inventors
CUTIE, Christopher, GIESING, Dennis
IPC Classifications
A61K 31/7068 20060101AFI20210707BHEP A61M 31/00 20060101ALI20210707BHEP A61K 9/00 20060101ALI20210707BHEP A61P 13/10 20060101ALI20210707BHEP A61P 35/00 20060101ALI20210707BHEP A61K 9/06 20060101ALI20210707BHEP A61K 47/36 20060101ALI20210707BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.